Answers are grounded in this paper and cite their sources.
Rabies remains a major public-health challenge, with pre-exposure vaccination strategies constrained by the need for multiple doses and repeated healthcare visits. Here we describe YF-RabG, a live-attenuated rabies vaccine candidate based on the yellow fever 17D (YF17D) vaccine backbone that stably expresses the rabies virus glycoprotein (RabG). YF-RabG exhibited an attenuated phenotype and favourable safety profile compared with parental YF17D across several preclinical models, including neonatal and immunocompromised mice. A single immunization induced robust humoral and cell-mediated immune responses in non-human primates. Rabies virus-neutralizing antibody titres readily exceeded the widely accepted correlate of protection in mice, hamsters and non-human primates by several orders. Accordingly, vaccination conferred protection against lethal rabies challenge in a range of stringent mouse models, maintained seroprotective antibody levels for at least one year, and increased following a boost using a licensed rabies vaccine. Furthermore, the YF17D vector was readily adapted to accommodate glycoproteins from distant lyssaviruses, generating protective vaccine candidates against Mokola, Lagos bat and Lleida bat lyssaviruses. Collectively, these findings identify YF-RabG as a promising single-dose rabies vaccine candidate and highlight the versatility of the YF17D platform for lyssavirus vaccine development.
No takes yet. Share an insight, caveat, or question.
Sánchez-Felipe et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: